Market Overview
End-stage renal diseases are associated with disorders related to the kidney and occur during chronic kidney disease, which adversely affects the functioning of the kidney.
The global end stage renal disease market size was valued US$ YY million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).
Download Free Sample: https://www.datamintelligence.com/download-sample/end-stage-renal-disease-market
Market Dynamics
Technological advancement products developed by the market players for renal diseases are expected to drive the market growth.
Chronic kidney failure, also known as end-stage renal disease, causes the kidneys to lose function over time, which can be harmful. Most renal failure patients go to dialysis clinics numerous times a week to have their blood filtered, a time-consuming, painful, and dangerous procedure. KidneyX is a public-private partnership established by the US Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) to accelerate kidney disease prevention, diagnosis, and treatment innovation. The Kidney Project, led by Shuvo Roy, Ph.D. of UC San Francisco and William Fissell, MD of Vanderbilt University Medical Center (VUMC), successfully implanted the smartphone-sized device for the preclinical evaluation of two essential components parts of its artificial kidney, the hemofilter and the bioreactor. KidneyX's Phase 1 Artificial Kidney Prize was presented to the team, one of six winning teams chosen from a worldwide competition for this advancement.
Moreover, the Kidney Project successfully tested the hemofilter, which removes waste products and toxins from the blood and the bioreactor, which simulates other kidney functions such as blood electrolyte balancing, in independent studies. The artificial kidney developed by The Kidney Project will imitate the exceptional quality of life experienced by kidney transplant recipients—the "gold standard" of kidney disease treatment—and improve on it. Additionally, In March 2021, Baxter International Inc. announced the US Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments. Therefore, it indicated that companies are taking initiatives to establish a strong footprint and launch technologically advanced products in the market.
Risks associated with the hemodialysis treatment are expected to hamper the market growth.
Certain risks associated with hemodialysis treatment increase when patients undergo HHD alone since no one is there to assist them in the event of a medical emergency. Patients may lose consciousness or become physically unable to rectify the health emergency if needles come out, blood is lost, or blood pressure is very low during solo HHD. During any health emergency, losing consciousness or becoming otherwise disabled could result in serious damage or death. Moreover, due to the length of treatment duration and the fact that therapy is administered when the patient and care partner are asleep, the dangers associated with hemodialysis treatment increase while doing nocturnal therapy. Blood access disconnects and blood loss during sleep, blood clotting due to decreased blood flow or greater treatment time, and delayed response to alarms while waking from sleep are only a few of the hazards. Therefore, ancillary devices and training are required when performing solo HHD
COVID-19 Impact Analysis
The COVID-19 outbreak has significantly impacted kidney disease incidence and management, including AKI, ESKD, GN, and kidney transplantation. Initial data from China revealed that patients with COVID-19 had a decreased risk of AKI. However, recent studies from North America show a significantly greater incidence, which is likely owing to the higher frequency of concomitant diseases such as hypertension, diabetes, and CKD. Moreover, those who receive outpatient in-center HD are in close contact with other patients and staff multiple times a week, putting them at even greater risk. Clinical presentation is atypical compared with patients not on dialysis, with patients with ESKD presenting without typical symptoms of cough and fever but fatigue and anorexia. The risk of in-hospital death is significantly higher among patients with ESKD than patients without ESKD, with older age and the need for mechanical ventilation increasing risk. Additionally, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. However, the situation is expected to improve gradually in the forecast period
Segment Analysis
-By End User
Hospital and Clinics*
Dialysis Centres
Others
-By Treatment And Diagnosis
Treatment
Kidney Transplantation
Dialysis
Peritoneal Dialysis
emodialysis
Wearable Artificial Kidney
Diagnosis
Blood Test
Urine Test
Imaging test
Others
Geographical Analysis
Asia-Pacific region holds the largest market share in the global end stage renal disease market
In 2020, Asia-Pacific accounted for the highest revenue share. The growth in the aging population, lifestyle stress, a large population base, improving quality of diagnosis, and growing patient affordability, presence of high disposable income and the high acceptance rate of technologically improved products and raising blood pressure and diabetes cases in the region are some of the factors due to which the market is expected to boost in the forecast period. For instance, according to the Asian Diabetics Prevention Initiatives, Asia will account for 60 percent of the world's diabetes population by 2020. A bigger contribution from China and India had 113.9 million and 65.1 million adults with diabetes, respectively. Both China and India may have nearly half a billion diabetic people by 2030.
Moreover, a report released by the Indian Government's national health portal indicates that 2.2 lakh new patients with end-stage renal disease (ESRD) are diagnosed each year, resulting in a demand for 3.4 crore dialysis treatments. In India, there were approximately 4,950 dialysis centers, most of which were in the private sector. As a result, the presence of several dialysis clinics in this region and an increase in the number of patients suffering from chronic renal and kidney illnesses are expected to boost market growth over the forecast period.
Competitive Landscape
Major key players in the end-stage renal disease market are B Braun Melsungen AG, Baxter International Inc, Medtronic PLC, Fresenius SE & Co. KGaA, Nipro Corporation, Asahi Kasei Medical Co., Trivitron Healthcare, Guangzhou MeCan Medical Limited, JMS North America Corporation and NxStage Medical. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which contribute to the growth of the end-stage renal disease market globally. For instance, In June 2021, Baxter launched the Sharesource Analytics 1.0 Digital Health Module to enhance the clinical management of home dialysis patients.
NxStage Medical, Inc.:
Overview:
NxStage Medical, Inc. is an American company that develops, manufactures, and markets systems to treat chronic kidney disease, acute kidney injury, and hypervolemia. It is a subsidiary of Fresenius Medical Care.
Product Portfolio:
System One: The NxStage System One is the portable hemodialysis system specifically designed for patients in their homes and is small enough to travel and bring their treatment supplies.
View Full Report: https://www.datamintelligence.com/research-report/end-stage-renal-disease-market
Enquiry Before Buying: https://www.datamintelligence.com/enquiry/end-stage-renal-disease-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Renal Disease Market: Information by Disease Type (Chronic Kidney Disease and End-Stage Renal Disease (ESRD)), by Treatment Type (Dialysis, Medication and Kidney Transplantation), by End User (Dialysis Centers, Hospital & Clinics, and Research and Academic Institutes) and by Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027The global renal diseases market has been growing at an incremental pace and is expected to attain USD 14291.2 Mn by the end of 2023, reveals Market Research Future (MRFR) in a minutely analyzed research report.
These factors in conjunction will shape the global renal disease market and help it achieve a CAGR of 6.3% over the forecast period of 2017-2023.Request Free Sample Copy at:https://www.marketresearchfuture.com/sample_request/3167 SegmentationThe global renal disease market has been segmented based on type, diagnosis, and treatment.
By diagnosis, the market has been segmented into Blood tests, Urine tests, imaging tests, removing a sample of kidney tissue for testing, and others.
The blood tests segment has been further segmented into Serum Creatinine, Glomerular Filtration Rate (GFR), Blood Urea Nitrogen (BUN), and fasting blood glucose test.
The urine test segment has been further segmented into Urinalysis, Protein urine test, Microalbuminuria test, Creatinine Clearance test.
The medication segment has been further segmented into High blood pressure medications, Medications to lower cholesterol levels, Medications to treat anemia, Medications to relieve swelling, and Medications to protect your bones.
